Supplementary Figure 8 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)

Key Points

• Genomic alterations detected in tumor tissue and plasma DNA help evaluate treatment responses.
• Patients treated with binimetinib show distinct response patterns based on NRAS mutation status.
• The presence of mutations is depicted using triangles for clarity in genomic assessment.
• This analysis highlights the importance of multi-sample genotyping in precision medicine.